Mounjaro®
Starting from £179.99/mo
Start journey Learn moreComing off Wegovy means stopping a once-weekly semaglutide injection that has been actively suppressing your appetite. Appetite typically returns within days to weeks of the final dose, and clinical evidence shows that a significant proportion of lost weight is regained without ongoing lifestyle support. There is no medically required tapering schedule for semaglutide, but the decision to stop should always be made with your prescriber. These are prescription-only medicines, and stopping — like starting — benefits from proper clinical oversight.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Unlike some medicines that require a gradual wind-down, there is no pharmacological reason to taper Wegovy before stopping. The NHS semaglutide medicines page does not describe a mandatory dose-reduction schedule before discontinuation. You can, in principle, simply stop after your last pen, but "can" and "should" are different questions.
The practical case for discussing the decision with your prescriber is strong. If you are stopping because of a side effect, they may be able to adjust your dose or approach. If you are stopping because treatment has run its course, they can help you plan what comes next. Stopping without a plan is the main reason people find weight regain harder to manage.
How you come off Wegovy matters less than what you put in place before the final dose lands. That is the conversation worth having. If you have not yet started treatment and are weighing up your options, our Wegovy overview sets out how the medicine works from the beginning.
Semaglutide has a half-life of roughly one week, which means meaningful concentrations remain in your system for several weeks after the last injection. Most people notice appetite beginning to increase within one to two weeks of stopping, with the full effect gone by around four to five weeks.
What catches people off guard is not just hunger returning, but its character. Wegovy dampens the brain signals that drive cravings and reward-eating, not just baseline hunger. When those signals come back, food can feel more compelling than it did before treatment, particularly in the first few weeks. How long Wegovy takes to wear off is covered in more detail on a dedicated page, because the timeline varies by dose and how long you have been using it.
Knowing this in advance lets you prepare. Having a structure for meals (even something as simple as eating at the same time each day) reduces the chance that the returning appetite catches you without a plan.
The STEP 1 extension study is the clearest data point available. Participants who stopped semaglutide 2.4mg after 68 weeks and received lifestyle support alone regained, on average, about two-thirds of the weight they had lost within one year of stopping, a finding published in the New England Journal of Medicine. NICE's appraisal of semaglutide acknowledges this trajectory, which is one reason NICE guidance (TA875) recommends Wegovy for a maximum of two years within a specialist service rather than as an open-ended prescription.
That figure can feel discouraging, but context helps. The participants who maintained the most weight were those who used the intervening period to build sustainable eating and movement habits, not those who relied on the medicine alone. Managing weight after Wegovy ends is a real, evidence-informed challenge, not an inevitability. Protein adequacy, adequate sleep, and consistent resistance training are the three factors the research points to most consistently.
For people thinking about what private treatment costs across its full course, our Wegovy price comparison sets out what UK providers typically charge and what those prices do and do not include.
Some people come off Wegovy not because they want to stop permanently, but because of a planned pregnancy, a surgical procedure, a period of financial pressure, or simply a break. Pausing and restarting is clinically possible, though each restart requires fresh clinical assessment rather than picking up where you left off, your prescriber needs to review your current weight, health status and any changes since your last dose before continuing.
A question our prescribers hear fairly often is whether stopping for a few weeks to "reset" tolerance is worthwhile. The evidence does not support tolerance as a clinically meaningful issue with semaglutide; if the medicine has stopped feeling effective, the more likely explanations are adherence, dietary patterns, or the need for a dose review. Addressing a plateau while still on Wegovy is worth exploring before stopping entirely. Similarly, if your concern is about semaglutide specifically rather than injectable treatment as a whole, switching from semaglutide to a different treatment is a conversation your prescriber can walk you through. Whatever direction you are heading, a structured plan made with a clinician is the thing that makes the difference. Start your free consultation with our prescribers if you would like to talk through your next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.